Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Fosamax Lawsuits Dismissed Again by March 2022 Preemption Ruling

March 29, 2022 By Law Offices of Thomas J. Lamb, P.A.

There are about 500 women who used Fosamax, suffered femur fractures, and then filed a product liability lawsuit against Merck. Their lawsuit had been pending in the federal court Fosamax MDL for ten years or more. In an unfortunate but not altogether unexpected development, in March 2022 their Fosamax lawsuits were dismissed a second time as a result of the federal preemption legal defense asserted by Merck. Understandably, For some of those women this will be adding insult to injury, so to speak.

In more detail, on March 23, 2022, these Fosamax lawsuits were dismissed by means of an opinion issued by Judge Freda Wolfson. Previously, these Fosamax lawsuits had been dismissed in 2013, but that ruling was appealed by the women who were plaintiffs in these femur fracture cases. After several years of legal procedures, these Fosamax lawsuits were remanded to the District of New Jersey in late 2019 by the U.S. Court of Appeals for the Third Circuit. This was the result of a May 2019 Supreme Court ruling in Merck Sharp & Dohme Corp. v. Doris Albrecht, et al., a Fosamax femur fracture case. Given this timeline, the women who filed these federal court Fosamax lawsuits had been waiting for this recent federal preemption ruling by Judge Wolfson for more than two years — only to find out, after that long wait, that Merck had prevailed again.

The March 23, 2022 Opinion for the federal court Fosamax lawsuits pending in the MDL captioned In Re Fosamax (Alendronate Sodium) Products Liability Litigation is lengthy and full of legal reasoning. In essence, however, Judge Wolfson ruled that:

  1. The FDA rejected a proposed warning submitted by Merck about a causal link between Fosamax and femur fractures because the FDA felt there was insufficient for such a Fosamax drug label change at that time; and,
  2. The evidence was clear and convincing that the FDA would not have approved a similar but differently worded warning if one had been submitted soon thereafter.

As pointed out above, the outcome of Judge Wolfson’s analysis was that the plaintiffs’ state-law failure-to-warn claims must be dismissed due to federal preemption, which is the ruling made by Judge Wolfson in her recent Fosamax MDL Opinion.

[View article at original source]

Filed Under: Unsafe Drugs Tagged With: Femur Fractures, Fosamax

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.